Although the pharmaceutical industry has remained reluctant to invest in such strategies, one of them, namely the prenatal replacement of missing EDA1 in children with the most prevalent ectodermal dysplasia, the X-linked hypohidrotic form (XLHED), is currently being evaluated in a worldwide clinical study (ClinicalTrials.gov identifier: NCT04980638). The gene discussed is EDA; the disease is X-linked hypohidrotic ectodermal dysplasia.